Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
Verve Therapeutics has raised $143.8M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2023.
Verve Therapeutics's investors include RA Capital Management, Eli Lilly, ARCH Venture Partners, Cormorant Asset Management, Janus Henderson Investors.
Verve Therapeutics is headquartered in Boston, United States.
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
Verve Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Verve Therapeutics — Funding & Investors." VCBacked, November 28, 2023, https://www.vcbacked.co/company/verve-therapeutics. Accessed July 20, 2026.
VCBacked. (2023). Verve Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/verve-therapeutics
{{cite web |title=Verve Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/verve-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated